Intraperitoneal paclitaxel prolongs survival in gastric cancer with peritoneal metastases

The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients with gastric cancer and peritoneal metastases, according to study results presented at Gastrointestinal Cancers Symposium.“Peritoneal metastasis is a common problem in patients with gastric cancer, and this unfortunately is not effectively treated by systemic chemotherapy alone given the presence of the peritoneal-plasma barrier,” Daryl Chia, MBBS, surgery resident at National University Health System in Singapore, said during his virtual presentation. “A numberRead More

Share on facebook
Share on twitter
Share on linkedin